Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study
CANCER RESEARCH. Bd. 82. H. 4. 2022
Erscheinungsjahr: 2022
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Luftner, Diana (Autor)
Brucker, Cosima (Autor)
Decker, Thomas (Autor)
Fasching, Peter (Autor)
Gohler, Thomas (Autor)
Jackisch, Christian (Autor)
Janssen, Jan (Autor)
Kohler, Andreas (Autor)
Ludtke-Heckenkamp, Kerstin (Autor)
van Mackelenbergh, Marion (Autor)
Marme, Frederik (Autor)
Nusch, Arnd (Autor)
Rautenberg, Beate (Autor)
Reimer, Toralf (Autor)
Schmidt, Marcus (Autor)
Weide, Rudolf (Autor)
Wimberger, Pauline (Autor)
Nabieva, Naiba (Autor)
Roos, Christian (Autor)
Wockel, Achim (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
